Correlation Between Crispr Therapeutics and Sarepta Therapeutics
Can any of the company-specific risk be diversified away by investing in both Crispr Therapeutics and Sarepta Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Crispr Therapeutics and Sarepta Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Crispr Therapeutics AG and Sarepta Therapeutics, you can compare the effects of market volatilities on Crispr Therapeutics and Sarepta Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Crispr Therapeutics with a short position of Sarepta Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Crispr Therapeutics and Sarepta Therapeutics.
Diversification Opportunities for Crispr Therapeutics and Sarepta Therapeutics
0.01 | Correlation Coefficient |
Significant diversification
The 3 months correlation between Crispr and Sarepta is 0.01. Overlapping area represents the amount of risk that can be diversified away by holding Crispr Therapeutics AG and Sarepta Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sarepta Therapeutics and Crispr Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Crispr Therapeutics AG are associated (or correlated) with Sarepta Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sarepta Therapeutics has no effect on the direction of Crispr Therapeutics i.e., Crispr Therapeutics and Sarepta Therapeutics go up and down completely randomly.
Pair Corralation between Crispr Therapeutics and Sarepta Therapeutics
Given the investment horizon of 90 days Crispr Therapeutics AG is expected to generate 1.61 times more return on investment than Sarepta Therapeutics. However, Crispr Therapeutics is 1.61 times more volatile than Sarepta Therapeutics. It trades about 0.03 of its potential returns per unit of risk. Sarepta Therapeutics is currently generating about -0.3 per unit of risk. If you would invest 4,600 in Crispr Therapeutics AG on August 24, 2024 and sell it today you would earn a total of 29.00 from holding Crispr Therapeutics AG or generate 0.63% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Crispr Therapeutics AG vs. Sarepta Therapeutics
Performance |
| Timeline |
| Crispr Therapeutics |
| Sarepta Therapeutics |
Crispr Therapeutics and Sarepta Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Crispr Therapeutics and Sarepta Therapeutics
The main advantage of trading using opposite Crispr Therapeutics and Sarepta Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Crispr Therapeutics position performs unexpectedly, Sarepta Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sarepta Therapeutics will offset losses from the drop in Sarepta Therapeutics' long position.| Crispr Therapeutics vs. Beam Therapeutics | Crispr Therapeutics vs. Editas Medicine | Crispr Therapeutics vs. Caribou Biosciences | Crispr Therapeutics vs. Verve Therapeutics |
| Sarepta Therapeutics vs. Krystal Biotech | Sarepta Therapeutics vs. PTC Therapeutics | Sarepta Therapeutics vs. Iovance Biotherapeutics | Sarepta Therapeutics vs. Madrigal Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Complementary Tools
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |